Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs

被引：29

作者：

Takeuchi, Akira ^{[1
]}

Oguri, Tetsuya ^{[1
]}

Sone, Kazuki ^{[1
]}

Ito, Keima ^{[1
]}

Kitamura, Yuki ^{[1
]}

Inoue, Yoshitsugu ^{[1
]}

Asano, Takamitsu ^{[1
]}

Fukuda, Satoshi ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Takakuwa, Osamu ^{[2
,3
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
]}

Maeno, Ken ^{[1
]}

Ito, Yutaka ^{[1
]}

Niimi, Akio ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Educ, Nagoya, Aichi, Japan

[3] Nagoya City Univ, Grad Sch Med Sci, Res Ctr Adv Med, Nagoya, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 10期

关键词：

Cytokeratin; 19; fragment; tumor marker; EGFR-TKI; non-small-cell lung cancer; RANDOMIZED PHASE-3 TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; ERLOTINIB; MUTATION; FRAGMENT; GEFITINIB; EFFICACY; AFATINIB;

D O I：

10.21873/anticanres.12018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Tyrosine kinase inhibitors (TKIs) directed against epidermal growth factor receptor (EGFR) are important in the treatment of non-small cell lung cancer (NSCLC), especially those harboring EGFR mutations. But little is known regarding the clinical value of serum tumor marker levels measured prior to treatment. Patients and Methods: We retrospectively reviewed 95 patients with advanced NSCLC treated with EGFR-TKIs, and inspected the relationship between serum tumor marker levels and clinical outcome. Results: Forty-three patients with an elevated serum level of cytokeratin 19 fragment (CYFRA 21-1) had shorter progression-free (PFS) and overall (OS) survival than 52 patients with normal serum CYFRA 21-1 levels (99 vs. 123.5 days p=0.011; and 385 vs. 607 days, respectively, p=0.001). Regardless of EGFR mutation status, patients had shorter progression-free survival when serum CYFRA 21-1 was elevated. Conclusion: Serum CYFRA 21-1 level may be a predictive factor for patients with NSCLC treated with EGFR-TKIs, regardless of EGFR mutation status.

引用

页码：5771 / 5776

页数：6

共 17 条

[1]

BROERS JLV, 1988, CANCER RES, V48, P3221

[2]

Fiala O, 2014, ANTICANCER RES, V34, P3205

[3]

Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[4]

Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[5]

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[6]

PUJOL JL, 1993, CANCER RES, V53, P61

[7]

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer:: results of a meta-analysis in 2063 patients [J].

Pujol, L ;

Molinier, O ;

Ebert, W ;

Daurès, JP ;

Barlesi, F ;

Buccheri, G ;

Paesmans, M ;

Quoix, E ;

Moro-Sibilot, D ;

Szturmowicz, M ;

Bréchot, JM ;

Muley, T ;

Grenier, J .

BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2097-2105

[8]

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[9]

Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[10]

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports [J].

Shukuya, Takehito ;

Takahashi, Toshiaki ;

Kaira, Rieko ;

Ono, Akira ;

Nakamura, Yukiko ;

Tsuya, Asuka ;

Kenmotsu, Hirotsugu ;

Naito, Tateaki ;

Kaira, Kyoichi ;

Murakami, Haruyasu ;

Endo, Masahiro ;

Takahashi, Kazuhisa ;

Yamamoto, Nobuyuki .

CANCER SCIENCE, 2011, 102 (05) :1032-1037

← 1 2 →